Synergistic drug combination for primary prevention of cardiovascular disease, especially in high-risk patients, comprising acetylsalicylic acid, HMG-CoA and optionally antihypertensive agent

摘要

New combinations (I) comprise (A) acetylsalicylic acid, (B) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and optionally (C) an antihypertensive agent. Independent claims are included for: (1) medicaments containing (I), optionally together with other suitable components; and (2) kits comprising (A), (B) and optionally (C), each together with a carrier in a separate container but with the containers within the same packaging. ACTIVITY : Cardiant; cerebroprotective; antilipemic; hypotensive; antidiabetic; antiarteriosclerotic; antianginal; vasotropic; anorectic; anticoagulant; antiinflammatory; laxative. MECHANISM OF ACTION : HMG-CoA reductase inhibitor.